The Lasker Awards are often seen as a stepping stone to the Nobel Prizes. So when biochemist Karikó and her longtime collaborator, University of Pennsylvania vaccine researcher Drew Weissman, captured a Lasker Award in 2021 for their work on synthetic messenger RNA technology, many took it as a sign: It may only be a matter…
"Fund people not projects" is easier said than done. A better way to fund science is to bend over backward to fund a truly diverse range of people and ideas, even including those perceived as unpopular, unworkable, and obscure.
"I'm not a very emotional person, but I just cried a little,” Katalin Karikó of BioNTech said of the health workers who clapped for her after she got the Covid vaccine she had a hand in developing.
Founders and investors have been allowed to bend the course of the pandemic to their private benefit. When a few people win big, everyone else loses.
This year’s Summit will feature expert voices from the FDA, leading pharmaceutical companies and other industry stakeholders BOSTON, MA – STAT, the nation’s must-read health, science, and medicine publication, recently announced that its inaugural 2021 STAT Breakthrough Science Summit will take place July 13-14. After a year that forced to innovation at unprecedented speed, the…
View Highlights About Come here for the cutting edge Technologies and procedures that would have been science fiction are now the reality of medicine. Our 2021 STAT Breakthrough Science Summit took attendees inside these innovations, examining how they're being developed, adopted, and paid for. We also explored the breakthroughs that haven't yet hit the market,…
"People want solutions. But then let's look at these Covid-19 vaccines. It was basic science, right?" says Ruth Lehmann, director of @WhiteheadInst.
The story of mRNA began is a tale of personal perseverance, eureka moments in the lab, soaring expectations — and an unprecedented flow of cash in biotech.
Moderna's caustic work environment has driven away top talent. There are signs the secretive startup has hit roadblocks with its most ambitious projects.
